CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Theodorescu, D.
Right arrow Articles by Gulding, K. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Theodorescu, D.
Right arrow Articles by Gulding, K. M.

Cell Growth & Differentiation, Vol 9, Issue 11 919-928, Copyright © 1998 by American Association of Cancer Research


ARTICLES

Epidermal growth factor receptor-regulated human bladder cancer motility is in part a phosphatidylinositol 3-kinase-mediated process

D Theodorescu, KR Laderoute and KM Gulding
Department of Urology, University of Virginia Health Sciences Center, Charlottesville 22908, USA.

Although overexpression of the epidermal growth factor receptor (EGFR) has been strongly associated with the transition from superficial to invasive human bladder cancer, the exact molecular pathways by which this gene effectively triggers or facilitates the invasive process are not completely understood. Because enhanced cellular motility is a prerequisite for invasion, we chose to determine how EGFR signaling impacts cellular motility of human bladder cancer in vitro in a cell model of human bladder cancer that closely mimics the human disease. Using a stable antisense approach to diminish EGFR expression, we obtained data that support the role of EGFR in mediating bladder cancer motility. These results also demonstrate that EGFR plays an important role in bladder cancer motility, even in the presence of a mutated and overexpressing Ras protein, and suggest the possibility that Ras-independent EGFR motility signaling is a significant pathway used by bladder cancer cells. In support of this concept, using specific pharmacological inhibition of phosphatidylinositol 3-kinase, we show that this mediator is involved in EGFR motility signaling in this system. Knowledge of the pathways used by EGFR to induce motility and subsequent invasion may lead to development of methods to prevent or retard the progression of aggressive superficial bladder tumors.


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
S. C. Smith, G. Oxford, A. S. Baras, C. Owens, D. Havaleshko, D. L. Brautigan, M. K. Safo, and D. Theodorescu
Expression of Ral GTPases, Their Effectors, and Activators in Human Bladder Cancer
Clin. Cancer Res., July 1, 2007; 13(13): 3803 - 3813.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Y. Jin, K. K. Iwata, A. Belldegrun, R. Figlin, A. Pantuck, Z.-F. Zhang, R. Lieberman, and J. Rao
Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model.
Mol. Cancer Ther., July 1, 2006; 5(7): 1754 - 1763.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. A. Memon, B. S. Sorensen, P. Meldgaard, L. Fokdal, T. Thykjaer, and E. Nexo
Down-Regulation of S100C Is Associated with Bladder Cancer Progression and Poor Survival
Clin. Cancer Res., January 15, 2005; 11(2): 606 - 611.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. L. Dominguez-Escrig, J. D. Kelly, D. E. Neal, S. M. King, and B. R. Davies
Evaluation of the Therapeutic Potential of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Preclinical Models of Bladder Cancer
Clin. Cancer Res., July 15, 2004; 10(14): 4874 - 4884.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
D. Sliva, M. T. Rizzo, and D. English
Phosphatidylinositol 3-Kinase and NF-{kappa}B Regulate Motility of Invasive MDA-MB-231 Human Breast Cancer Cells by the Secretion of Urokinase-type Plasminogen Activator
J. Biol. Chem., February 1, 2002; 277(5): 3150 - 3157.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
H.-L. Cheng, M. L. Steinway, J. W. Russell, and E. L. Feldman
GTPases and Phosphatidylinositol 3-Kinase Are Critical for Insulin-like Growth Factor-I-mediated Schwann Cell Motility
J. Biol. Chem., September 1, 2000; 275(35): 27197 - 27204.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
M. A. Adelsman, J. B. McCarthy, and Y. Shimizu
Stimulation of beta 1-Integrin Function by Epidermal Growth Factor and Heregulin-beta Has Distinct Requirements for erbB2 but a Similar Dependence on Phosphoinositide 3-OH Kinase
Mol. Biol. Cell, September 1, 1999; 10(9): 2861 - 2878.
[Abstract] [Full Text]


Home page
J Biol ChemHome page
H.-L. Cheng, M. L Steinway, J. W Russell, and E. L Feldman
GTPases and Phophatidylinositol-3 Kinase are Critical for Insulin-like Growth Factor-I Mediated Schwann Cell Motility
J. Biol. Chem., May 26, 2000; (2000) 25342001.
[Abstract]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1998 by the American Association of Cancer Research.